Enas N - Search Results

1

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.

Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Robertson MJ, et al. Among authors: enas n. J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389337 Clinical Trial.

2

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS. Carducci MA, et al. Among authors: enas n. J Clin Oncol. 2006 Sep 1;24(25):4092-9. doi: 10.1200/JCO.2005.05.3447. J Clin Oncol. 2006. PMID: 16943527 Clinical Trial.

3

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE. Rademaker-Lakhai JM, et al. Among authors: enas n. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81. doi: 10.1158/1078-0432.CCR-06-2912. Clin Cancer Res. 2007. PMID: 17671132 Clinical Trial.

4

In Vivo Measurements of Tumor Metabolism and Growth after Administration of Enzastaurin Using Small Animal FDG Positron Emission Tomography.

Pollok KE, Lahn M, Enas N, McNulty A, Graff J, Cai S, Hartwell JR, Ernstberger A, Thornton D, Brail L, Hutchins G. Pollok KE, et al. Among authors: enas n. J Oncol. 2009;2009:596560. doi: 10.1155/2009/596560. Epub 2009 May 27. J Oncol. 2009. PMID: 19503801 Free PMC article.

5

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE. Ganjoo KN, et al. Among authors: enas nh. Leuk Lymphoma. 2015 Jan;56(1):42-8. doi: 10.3109/10428194.2014.911859. Epub 2014 Jul 14. Leuk Lymphoma. 2015. PMID: 24717109 Clinical Trial.

6

Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.

Stevenson JP, Sun W, Gallagher M, Johnson R, Vaughn D, Schuchter L, Algazy K, Hahn S, Enas N, Ellis D, Thornton D, O'Dwyer PJ. Stevenson JP, et al. Among authors: enas n. Clin Cancer Res. 2002 Aug;8(8):2524-9. Clin Cancer Res. 2002. PMID: 12171879 Clinical Trial.

7

Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.

Jänne PA, Paz-Ares L, Oh Y, Eschbach C, Hirsh V, Enas N, Brail L, von Pawel J. Jänne PA, et al. Among authors: enas n. J Thorac Oncol. 2014 Jan;9(1):126-31. doi: 10.1097/JTO.0000000000000037. J Thorac Oncol. 2014. PMID: 24346102 Free article. Clinical Trial.

8

Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer.

Münster PN, Buzdar A, Dhingra K, Enas N, Ni L, Major M, Melemed A, Seidman A, Booser D, Theriault R, Norton L, Hudis C. Münster PN, et al. Among authors: enas n. J Clin Oncol. 2001 Apr 1;19(7):2002-9. doi: 10.1200/JCO.2001.19.7.2002. J Clin Oncol. 2001. PMID: 11283133 Clinical Trial.

9

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R. Storniolo AM, et al. Among authors: enas nh. Cancer. 1999 Mar 15;85(6):1261-8. Cancer. 1999. PMID: 10189130

10

Randomized phase II studies and their ethics.

Abratt RP, Reece WH, Enas NH, Stephens R. Abratt RP, et al. J Clin Oncol. 2005 Dec 20;23(36):9443. doi: 10.1200/JCO.2005.04.0832. J Clin Oncol. 2005. PMID: 16361651 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters